Comparative Pharmacology
Head-to-head clinical analysis: UNASYN versus V CILLIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNASYN versus V CILLIN K.
UNASYN vs V-CILLIN K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
Penicillin V exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
0.5–1 hour (normal renal function); prolonged to 2–6 hours in renal impairment.
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Renal: 60-90% unchanged via tubular secretion and glomerular filtration; minor biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic